Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)

NCT05002127 is registered in ClinicalTrials.gov with ALX Oncology Inc. as lead sponsor.

NCT NCT05002127
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05002127 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)
Lead sponsor
ALX Oncology Inc.
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
January 15, 2022
Completion date
June 30, 2026
Enrollment
127 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma, gastric cancer, gastroesophageal junction adenocarcinoma